

Supplementary material

Reference specification and identification numbers

- 1 = Wistar rat exposure from GD7-PD16 by gavage, AR antagonism in R1881-stimulated Chinese Hamster Ovary (CHO K1) cells (Hass et al., 2012)
- 2 = Wistar rat exposure from GD7-PD16 by gavage, testosterone measurements in testes (Taxvig et al., 2007)
- 3 = continuous administration over 2 generations of Wistar rat exposure in the feed (Hellwig and Hildebrand, 1992)
- 4 = Wistar rat exposure from GD6-15 by gavage (Hellwig and Hildebrand, 1989; Hellwig and Hildebrand, 1990b)
- 5 = Wistar rat exposure from GD6-19 by gavage (Schneider, 2001; Schneider, 2002)
- 6 = Himalayan rabbits exposure from GD7-19 by gavage (Hellwig and Hildebrand, 1990a)
- 7 = Wistar rat exposure from GD7-21 by gavage, testosterone measurement in testes (Taxvig et al., 2008)
- 8 = Sprague-Dawley rat exposure GD8, 9, 10, 11, 12, 13, 14, or 15 by gavage (Mineshima et al., 2012)
- 9 = Wistar rat exposure from GD6-15 by gavage (Amaral and Nunes, 2009; Amaral and Nunes, 2008)
- 10 = Holtzman rat exposure GD1-8 by gavage, progesterone measurements in serum (Cummings et al., 1997)
- 11 = oral rabbit or rat exposure before fertilization, GD1–7, GD7–17 or during perinatal period as reviewed by (Marotta and Tiboni, 2010)
- 12 = Wistar rat exposure from GD7-PD17 by gavage, testosterone measurements in plasma and testes (Vinggaard et al., 2005)
- 13 = Sprague-Dawley rat exposure from GD14-18 by gavage, AR antagonism in dihydrotestosterone-stimulated stably transfected MDA-kb2 cells (Noriega et al., 2005)
- 14 = Wistar rat exposure on GD7, GD11, and GD15 by gavage (Dmytriyeve et al., 2012)
- 15 = continuous administration over 2 generations of CD rats (Cozens et al., 1982)
- 16 = Sprague-Dawley rat exposure from GD14-18 by gavage, hormone measurement *ex vivo* in testes (Blystone et al., 2007)
- 17 = Wistar rat exposure from GD7-PD16 by gavage, steroidogenesis in human adrenocortical carcinoma (H295R) cells, testosterone measurements in plasma and testes (Laier et al., 2006)
- 18 = CD rat exposure GD1-20 by gavage (Beswick, 1980)
- 19 = Chinchilla rabbit exposure GD6-18 by gavage (Becker et al., 1988)
- 20 = continuous administration over 2 generations of CD rats (Borders et al., 1985)
- 21 = CD rat exposure during pregnancy by gavage (Marcsisin et al., 1987)
- 22 = New Zealand White rabbit exposure during pregnancy by gavage (Raab et al., 1986)
- 23 = Wistar rat exposure from GD6-PD120 (♂) and GD6-PD98 (♀) in the feed. NB minor disagreement in the highest dose level at PD1-PD22 reported in the two articles (Goetz et al., 2007; Rockett et al., 2006)
- 24 = Sprague-Dawley rat exposure from GD14-PD42 by gavage (Moser et al., 2001)
- 25 = Chinchilla rabbit exposure during prenatal development by gavage (Becker and Biedermann, 1995b; Becker et al., 1988b)
- 26 = NMRI mice exposure during prenatal development by gavage (Becker and Biedermann, 1995a)
- 27 = New Zealand White rabbit exposure during prenatal development by gavage (Hoberman, 2005)
- 28 = Wistar rat exposure during prenatal development by gavage (Becker et al., 1988a)
- 29 = continuous administration over 2 generations of Wistar rats in the feed (Toung et al., 2005; Eiben, 1987)
- 30 = AR antagonism in R1881-stimulated Chinese Hamster Ovary (CHO K1) cells, steroidogenesis in human adrenocortical carcinoma (H295R) cells, anti-estrogenicity and aromatase inhibition in MCF-7 cells (Kjaerstad et al., 2010b)
- 31 = AR antagonism in R1881-stimulated Chinese Hamster Ovary (CHO K1) cells, steroidogenesis in human adrenocortical carcinoma (H295R) cells (Kjaerstad et al., 2010a)
- 32 = AR antagonism in R1881-stimulated Chinese Hamster Ovary (CHO K1) cells (Vinggaard et al., 2008)
- 33 = AR antagonism in R1881-stimulated Chinese Hamster Ovary (CHO K1) cells, AhR-CALUX assay employing stably transfected rat hepatoma H4IIE cells, steroidogenesis in human adrenocortical carcinoma (H295R) cells, anti-estrogenicity and aromatase inhibition in MCF-7 cells (Kjaerstad et al., 2007)
- 34 = human adrenocortical carcinoma (H295R)/R2C cells (Heneweer et al., 2004)
- 35 = human/rat 4-androstenedione-treated granulosa cells (Wuttke, 2001)
- 36 = human baculovirus/insect cell-expressed aromatase supersomes and DBF as substrate (Trosken et al., 2004)
- 37 = human adrenocortical carcinoma (H295R) cells (Hecker et al., 2006)
- 38 = human adrenocortical carcinoma (H295R) cells measuring combined/direct aromatase inhibition (Higley et al., 2010)
- 39 = human adrenocortical carcinoma (H295R) cells (Villeneuve et al., 2007)
- 40 = human adrenocortical carcinoma (H295R) cells (Rijk et al., 2012)
- 41 = human adrenocortical carcinoma (H295R) cells (Nielsen et al., 2012)
- 42 = LH-stimulated mouse Leydig cells (Schurmeyer and Nieschlag, 1984)
- 43 = human fetal testes recovered during the first trimester (7–12 weeks) of gestation (Lambrot et al., 2009)
- 44 = gonadotropin-stimulated adult rat Leydig cells (Pont et al., 1982)
- 45 = human/canine/rat testicular cells (De Coster et al., 1989)
- 46 = baculovirus/insect cell-expressed aromatase (supersomes) and DBF as substrate (Stresser et al., 2000)

- 47 = baculovirus/insect cell-expressed aromatase (supersomes) and DBF as substrate (Kragie et al., 2002)
- 48 = ovine/human placental microsomes and tritiated androstenedione as substrate (France et al., 1987)
- 49 = human placental microsomes and tritiated androstenedione/testosterone as substrate (Ayub and Levell, 1988)
- 50 = human placental microsomes and tritiated androstenedione as substrate (Mason et al., 1985; Mason et al., 1987)
- 51 = baculovirus/insect cell-expressed aromatase supersomes and DBF as substrate (Trosken et al., 2006)
- 52 = AR antagonism in R1881-stimulated Chinese Hamster Ovary (CHO K1) cells, ER antagonism in MCF-7 cells, aromatase inhibition in human placental microsomes and tritiated androstenedione as substrate (Andersen et al., 2002)
- 53 = AR antagonism in R1881-stimulated Chinese Hamster Ovary (CHO K1) cells (Vinggaard et al., 2002)
- 54 = MDA-BK2 cells using androstenedione/testosterone/17 β -trenbolone as substrate (Blake et al., 2010)
- 55 = AR antagonism in R1881-stimulated Chinese Hamster Ovary (CHO K1) cells (Birkhoj et al., 2004)
- 56 = transient transfected MCF-7 cells/stable transfected MVLN cells (Bonefeld-Jorgensen et al., 2005)
- 57 = AhR-CALUX assay employing stably transfected rat hepatoma H4IIE/human TV101L hepatoma cell lines, the agonist TCDD was used when investigating the antagonistic response (Long et al., 2003)
- 58 = stably transfected mouse hepatoma Hepa1c1c7 (DR-EcoScreen) cells (Takeuchi et al., 2008)
- 59 = rhCG-stimulated murine BLTK1 Leydig cells (Forgacs et al., 2012)
- 60 = human adrenocortical carcinoma (H295R) cells and tritiated androstenedione as substrate. The effect of tebuconazole may be largely due to cytotoxicity (Sanderson et al., 2002)
- 61 = human placental microsomes and tritiated androstenedione as substrate (Vinggaard et al., 2000)
- 62 = human choriocarcinoma JEG-3 cells exposure 2h/24h. NB. Two different IC50-values are stated for propiconazole after 2h exposure (Laville et al., 2006)
- 63 = human adrenocortical carcinoma (H295R) cells (Goetz et al., 2009)
- 64 = human ovarian granulosa-like carcinoma (KGN) cells (Ohno et al., 2004)
- 65 = Wistar rats exposure from GD7-PD16 by gavage (Jacobsen et al., 2012)
- 66 = Wistar rat exposure from GD1-6 or GD6-15 by gavage (de Castro and Maia, 2012)
- 67 = Sprague–Dawley rat exposure from GD14-18 by gavage, testosterone measurements *ex vivo* in testes (Wilson et al., 2004)
- 68 = CD-1 mice exposure for 90 days in the feed (Wahle et al., 2004)